June 03, 2009
1 min read
Save

Foldable iris-fixated phakic IOL proves effective, stable for myopic correction

Ophthalmology. 2009;116(4):671-677.

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A foldable iris-fixated phakic IOL was effective and predictable in correcting myopia in phakic eyes, according to 2-year results of a multicenter trial.

The study authors presented outcomes of the foldable Artiflex iris-fixated phakic IOL (Ophtec).

"Complications were comparable with complications that have been reported previously of the Artisan [phakic] IOL, the only exception being a higher incidence of iris pigment precipitates (4.8% at 2 years after surgery)," they said.

The prospective, non-randomized trial included 290 eyes of 191 patients 18 to 60 years old with spherical equivalent of –7.33 D ± 2.60 D (range, –12.63 D to –1.5 D). All eyes underwent implantation of the Artiflex with an optic zone of 6 mm. IOL power ranged from –2 D to –12 D, the authors said.

Outcome measures assessed at 2-year follow-up were best corrected visual acuity, uncorrected visual acuity, refraction and endothelial cell count.

At 2 years, 97.2% of eyes had UCVA of 20/40 or better; all eyes had BCVA of 20/40 or better. A gain of one or more lines of BCVA was seen in 49.9% of eyes; 0.8% lost two or more lines. Mean endothelial cell count change was –0.05% at 6 months, 1.79% at 1 year and –1.07% at 2 years, the authors said.